Media about us

• Epic uncovers prostate cancer biomarker

  09 January 2017 Lori Lesko / DDNEWS Cancer Research News

  

  Biotech company Epic Sciences’ focus on circulating tumor cells (CTCs) will not only advance the clinical use of liquid biopsies and improve how metastatic cancer is treated, it says, but also identified a unique CTC biomarker in patients with metastatic prostate cancer who respond to PARP inhibitors cancer drugs in development.

• Raindrop Vision Procedure Designed to Reduce or Eliminate Reading Glasses Now Available in Alabama.

  05 January 2017 PRWeb

  

  The All-New Raindrop® Near Vision Inlay is designed to improve near vision so you can once again see fine print, menus and your phone without the hassle of reading glasses.

• Pfizer Inc. Considerable Stocks on Returns- Horizon Pharma plc

  29 December 2016 Seneca Globe

  

  Pfizer Inc. (NYSE:PFE) , stock eased up around 0.15% in early session as its gaining volume of 11.21 Million. US pharma giant, Pfizer (NYSE:PFE) and Russia’s NovaMedica, a company established in 2012 by Russian high-technology investment fund Rusnano and American healthcare fund Domain Associates, have completed the last stage of negotiations for a long-term strategic partnership designed to transfer the rights and technologies for the production of more than 30 life-saving and essential drugs from the Pfizer product portfolio.

• Pfizer Inc. and NovaMedica have completed the last stage of negotiations

  29 December 2016 BM - Breaking News and Headlines

  

  Pfizer Inc. (NYSE:PFE) and Russia’s NovaMedica, a company established in 2012 by Russian high-technology investment fund Rusnano and American healthcare fund Domain Associates, have completed the last stage of negotiations for a long-term strategic partnership designed to transfer the rights and technologies for the production of more than 30 life-saving and essential drugs from the Pfizer product portfolio.

• Pfizer and NovaMedica complete strategic partnership

  28 December 2016 The Pharma Letter

  

  US pharma giant Pfizer (NYSE: PFE) and Russia’s NovaMedica, a company established in 2012 by Russian high-technology investment fund Rusnano and American healthcare fund Domain Associates, have completed the last stage of negotiations for a long-term strategic partnership designed to transfer the rights and technologies for the production of more than 30 life-saving and essential drugs from the Pfizer product portfolio.

• US-Russia Relations: Why Donald Trump is Right to Look East

  19 December 2016 David Morgan / Global Research

  

  ​US President-elect Donald J Trump has been widely criticised by his liberal critics in the media and by Democratic Party opponents for wanting to normalise his country’s relations with Russia and to adopt a more balanced approach towards Moscow.

• Nurse to get newly improved cornea inlay to improve near vision

  07 December 2016 The Tennessean

  

  Diane McTaggart will be among the first Middle Tennesseans to undergo a newly approved device to treat loss of near vision associated with aging, also known as presbyopia. The U.S. Food and Drug Administration approved ReVision Optics' Raindrop Near Vision Inlay — a device that gets implanted in the cornea — this summer. The tiny inlay looks like a small contact lens, albeit smaller than a needle's eye, that is made out of hydrogel material. It's approved for people aged 41 to 65 who need reading glasses for small print but do not glasses for distance vision, and have not had cataract surgery.

• Minimally invasive surgical solutions for presbyopia

  28 November 2016 Jeffrey Whitman, MD / Optometry Times

  

  The three inlays have different designs and correct presbyopia via different mechanisms. Results from FDA studies for both the Kamra inlay and Raindrop Near Vision Inlay showed patients achieved very good near and intermediate uncorrected visual acuity. Maintenance of good uncorrected binocular distance vision is a feature of all of the corneal inlays.

• 5 Biotech IPOs Lead The Way In 2016

  25 November 2016 Don Dion / Seeking Alpha

  

  While the IPO market was relatively weak in 2016 overall, biopharma IPOs excelled. We have been particularly impressed with AveXis, Clearside Biomedical, Protagonist Therapeutics, Reata Pharma, and bluebird bio. We plan to initiate or build on existing long positions in these companies heading into 2017.

• Sun Pharma moves on Russia with deal for control of JSC Biosintez

  23 November 2016 Eric Palmer / Fierce Pharma

  

  India’s Sun Pharma is joining the growing number of companies snagging a portfolio and local manufacturing in Russia with a deal worth $60 million to buy control of a Russian drug producer. Pfizer last summer announced its third deal in Russia to establish local manufacturing. It and Russia’s NovaMedica are building a manufacturing plant in the Kaluga region which they say will be producing drugs by 2020.